Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease

Mayyas,Fadia  A.; Al-Jarrah,Mohammad  I.; Ibrahim,Khalid  S.; Alzoubi,Karem  H.

doi:10.3892/etm.2014.2034

Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease

Authors:
- Fadia A. Mayyas
- Mohammad I. Al-Jarrah
- Khalid S. Ibrahim
- Karem H. Alzoubi
View Affiliations

Affiliations: Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, Department of General Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan, Princess Muna Heart Institute, King Abdullah University Hospital, Irbid 22110, Jordan
Published online on: October 17, 2014 https://doi.org/10.3892/etm.2014.2034
Pages: 1951-1957

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation plays a pivotal role in the etiology of coronary artery disease (CAD). Myeloperoxidase (MPO) is a potent inflammatory factor and a critical modulator of coronary inflammation and oxidative stress. The goal of this study was to determine the impact of the plasma MPO (pMPO) level and neutrophil/lymphocyte ratio on the clinical characteristics and outcomes of patients with CAD. Blood samples were collected from 210 patients with underlying chest pain or recent myocardial infarction (MI) prior to coronary angiography in order to measure pMPO levels. The pMPO levels and neutrophil/lymphocyte ratio were correlated with clinical characteristics and outcomes following catheterization. The pMPO level and neutrophil/lymphocyte ratio were higher in patients with recent MI than in patients with CAD (coronary occlusion ≥50%) or without CAD (coronary occlusion <50%). Patients with ST segment elevated MI (STEMI) had a higher neutrophil/lymphocyte ratio relative to patients with non‑STEMI. The pMPO level was identified to correlate with the neutrophil/lymphocyte ratio and the need for coronary artery reperfusion by coronary artery bypass surgery or percutaneous coronary intervention. Patients who were taking aspirin had lower pMPO levels and neutrophil/lymphocyte ratio compared with those who were not taking aspirin. The plasma neutrophil/lymphocyte ratio was negatively associated with the left ventricular ejection fraction at baseline and the 30‑day follow‑up, whereas pMPO showed no correlation. Multivariate analysis indicated that the pMPO level was positively associated with MI, the neutrophil/lymphocyte ratio and coronary intervention. The preoperative use of aspirin was associated with a lower pMPO level and neutrophil/lymphocyte ratio. In conclusion, pMPO is positively associated with MI, the neutrophil/lymphocyte ratio and coronary intervention. The preoperative use of aspirin is associated with a lower pMPO level and neutrophil/lymphocyte ratio. pMPO may serve as a predictor of coronary intervention and as a potential therapeutic target for the reduction of inflammation in patients with CAD.

View Figures

View References

1	Fitchett DH, Theroux P, Brophy JM, et al: Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment - part 2: ST-segment elevation myocardial infarction. Can J Cardiol. 27(Suppl A): S402–S412. 2011. View Article : Google Scholar
2	Duivenvoorden R, Mani V, Woodward M, et al: Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging. 6:1087–1094. 2013. View Article : Google Scholar : PubMed/NCBI
3	Naruko T, Ueda M, Haze K, et al: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 106:2894–2900. 2002. View Article : Google Scholar : PubMed/NCBI
4	van der Wal AC, Becker AE, van der Loos CM and Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:36–44. 1994.
5	Mauriello A, Sangiorgi G, Fratoni S, et al: Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol. 45:1585–1593. 2005. View Article : Google Scholar
6	Kaya MG, Akpek M, Lam YY, et al: Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol. 168:1154–1159. 2013. View Article : Google Scholar
7	Danesh J, Wheeler JG, Hirschfield GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 350:1387–1397. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhang R, Brennan ML, Shen Z, et al: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 277:46116–46122. 2002. View Article : Google Scholar : PubMed/NCBI
9	Podrez EA, Schmitt D, Hoff HF and Hazen SL: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 103:1547–1560. 1999. View Article : Google Scholar : PubMed/NCBI
10	Zheng L, Nukuna B, Brennan ML, et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 114:529–541. 2004. View Article : Google Scholar : PubMed/NCBI
11	Vita JA and Loscalzo J: Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation. 106:164–166. 2002. View Article : Google Scholar : PubMed/NCBI
12	Sugiyama S, Kugiyama K, Aikawa M, et al: Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 24:1309–1314. 2004. View Article : Google Scholar
13	Tang WH, Wu Y, Nicholls SJ and Hazen SL: Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem. 57:33–39. 2011. View Article : Google Scholar
14	Proposal for the multinational monitoring of trends and determinants in cardiovascular disease and protocol (MONICA Project). WHO/MNC/821. Cardiovascular Disease Unit, World Health Organization; Geneva: 1982
15	Cavusoglu E, Ruwende C, Eng C, et al: Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 99:1364–1368. 2007.
16	Zhang R, Brennan ML, Fu X, et al: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2136–2142. 2001. View Article : Google Scholar : PubMed/NCBI
17	Baldus S, Heeschen C, Meinertz T, et al; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 108:1440–1445. 2003. View Article : Google Scholar : PubMed/NCBI
18	Chang LT, Chua S, Sheu JJ, et al: Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 73:726–731. 2009. View Article : Google Scholar
19	Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ and Kaski JC: Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol. 101:1537–1540. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kaya MG, Yalcin R, Okyay K, et al: Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 39:500–506. 2012.PubMed/NCBI
21	Miura T: Direction of strategic use: a new classification of non-steroidal anti-inflammatory drugs based on reactivity with peroxidase. Yakugaku Zasshi. 133:681–689. 2013.(In Japanese).
22	Coimbra LS, Steffens JP, Muscará MN, Rossa C Jr and Spolidorio LC: Antiplatelet drugs reduce the immunoinflammatory response in a rat model of periodontal disease. J Periodontal Res. 2013.PubMed/NCBI
23	Eickmeier O, Seki H, Haworth O, et al: Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol. 6:256–266. 2013. View Article : Google Scholar : PubMed/NCBI
24	King M, Kingery JE and Casey B: Diagnosis and evaluation of heart failure. Am Fam Physician. 85:1161–1168. 2012.
25	Brügger-Andersen T, Hetland Ø, Ponitz V, Grundt H and Nilsen DW: The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. Thromb Res. 119:415–421. 2007.